Compare ArcelorMittal SA (MT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs GeneDx Holdings Corp — how do they compare? ArcelorMittal SA trades at $66.25 (market cap $50.01B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: ArcelorMittal SA is far larger — about 27.8× GeneDx Holdings Corp's market cap, and ArcelorMittal SA pays a 0.91% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MT | WGS | |
|---|---|---|
Market Cap | $50.01B | $1.80B |
Sector | Basic Materials | Technology |
52-Week High | $71.65 | $167.51 |
52-Week Low | $30.39 | $34.51 |
Enterprise Value | $59.33B | $1.80B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
